Next Article in Journal
Humic Acids Preparation, Characterization, and Their Potential Adsorption Capacity for Aflatoxin B1 in an In Vitro Poultry Digestive Model
Next Article in Special Issue
Is Botulinum Toxin Effective in Treating Orofacial Neuropathic Pain Disorders? A Systematic Review
Previous Article in Journal
Botulinum Toxin Treatment of Motor Disorders in Parkinson Disease—A Systematic Review
Previous Article in Special Issue
Neurophysiological Basis of Deep Brain Stimulation and Botulinum Neurotoxin Injection for Treating Oromandibular Dystonia
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Toxins
Volume 15
Issue 2
10.3390/toxins15020082
toxins-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques

by
Sung Ok Hong
Department of Oral and Maxillofacial Surgery, Kyung Hee University College of Dentistry, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea
Toxins 2023, 15(2), 82; https://doi.org/10.3390/toxins15020082
Submission received: 30 November 2022 / Revised: 13 January 2023 / Accepted: 15 January 2023 / Published: 17 January 2023
(This article belongs to the Special Issue Therapeutic Uses and Efficacy of Botulinum Toxin in Orofacial Medicine: From the Standpoint of Dental Professionals)
Browse Figures
Review Reports Versions Notes

Abstract

:
Botulinum toxin (BoNT) is an anaerobic rod-shaped-neurotoxin produced by Clostridium botulinum, that has both therapeutic and lethal applications. BoNT injection is the most popular cosmetic procedure worldwide with various applications. Patients with dynamic wrinkles in areas such as the glabella, forehead, peri-orbital lines, nasal rhytides, and perioral rhytides are indicated. Excessive contraction of muscles or hyperactivity of specific muscles such as bulky masseters, cobble stone chins, gummy smiles, asymmetric smiles, and depressed mouth corners can achieve esthetic results by targeting the precise muscles. Patients with hypertrophic submandibular glands and parotid glands can also benefit esthetically. There are several FDA-approved BoNTs (obabotuli-numtoxinA, abobotulinumtoxinA, incobotulinumtoxinA, letibotulinumtoxinA, prabotulinumtox-inA, daxibotulinumtoxinA, rimbotulinumtoxinB) and novel BoNTs on the market. This paper is a narrative review of the consensus statements of expert practitioners and various literature on the injection points and techniques, highlighting both the Asian and Caucasian population separately. This paper can serve as a practical illustrative guide and reference for optimal, safe injection areas and effective doses for application of BoNT in the face and oral and maxillofacial area. The history of BoNT indications, contraindications, and complications, and the merits of ultrasonography (US)-assisted injections are also discussed.
Keywords:
botulinum toxin; Botox; cosmetic treatment; esthetic treatment; maxillofacial; dentist; injection; BoNT; non-invasive; face; wrinkles; aging; beauty; facial anatomy; toxin; rhytides
Key Contribution: This review focuses on esthetic procedures that both dentists and physicians can perform in the oral and maxillofacial areas. The injection amount of BoNT, depth, and points of forehead rhytides, glabella, crow’s feet, infraorbital rhytides, bunny lines, perioral rhytides, bulky jaw, marionette lines, cobblestone chin, and gummy smile are discussed and animated in details based on expert panel opinion summaries.

1. Introduction

Facial beauty, though slightly different in each ethnicity, tends to have a universal rule. A balanced, symmetrical, oval face with harmonious features is perceived as attractive and youthful [1,2,3]. Esthetic concerns are different by age groups with younger groups focusing more on a smooth contour and volume reduction, while older groups focus on wrinkles and improving volume loss [3]. Facial expression muscles are different from other muscular parts of the body because they have soft tissue attachments to the skin through the superficial musculoaponeurotic system, rather than to the bone [4]. Since contracting superficial skin moves in coordination with the underlying muscles, dynamic wrinkles perpendicular to the muscles develop [4,5]. These developed dynamic rhytides lead to atrophy of the dermis and pleating in the skin, which may give an impression of an angry, sad, or aging face. Botulinum neurotoxin (BoNT) can significantly soften dynamic wrinkles and even provide a lifting effect [6,7]. BoNT injection is the most popular cosmetic procedure worldwide with various applications. It can treat not only facial wrinkles but also a wide range of dermatologic, ophthalmologic, oral and maxillofacial, neurologic, urologic, and gynecologic conditions [8,9,10,11]. The reversible characteristics and versatile applications of BoNT make it widely preferable for both cosmetic and therapeutic treatment.
BoNT is a neurotoxin produced by the anaerobic rod-shaped bacterium Clostridium botulinum, and has both medical and lethal applications [12]. It is the most potent biological toxin known with an estimated lethal dose at 0.09 to 0.15 µg (IV or IM), 0.70 to 0.90 µg (inhalation), and 70 µg (PO) [11,13]. C. botulinum produces seven BoNT serotypes (A, B, C, D, E, F, G) [14,15]. An eighth serotype (X) was identified from C. botulinum strain 111 using bioinformatics techniques [15,16]. The most potent serotype is A, followed by B and F [17,18]. BoNT serotypes A and B are the only ones that have been manufactured for clinical use [7]. The effects of BoNT appear after approximately 2–3 days on rhytides and 3 weeks on larger muscles, and last between 3 and 6 months [19,20,21].
In 1829, a German medical officer and poet named Justinus Kerner (1786–1862) reported lethal food poisoning due to rotten sausages (botulus, Latin for sausage). In 1897, Emile von Ermengem investigated an outbreak of botulism due to raw ham in Belgium and found spore-forming anaerobic bacteria, Bacillus botulinum [19]. The outbreak of World War I and II weaponized BoNT by investigating the effect on muscle contraction [22]. In 1944, Edward Schantz cultured and isolated C. botulinum, and later in 1949, Arnold Burgen discovered the mechanism of how BoNT works by blocking acetylcholine release from the neuromuscular junction leading to muscular paralysis [11,23].
The first suggestion of using BoNT for therapeutic use was in 1973. An American ophthalmologist Alan B. Scott published the results of strabismus treatment using BoNT on monkeys. In 1977, he became the first person to use BoNT to treat blepharospasm and strabismus, and later founded the company Oculinum [24]. In 1987, Carruthers and Carruthers observed that BoNT treatment in patients with blepharospasm enhanced their glabellar lines and reported its cosmetic effect [25]. Soon after the United States Food and Drug Administration (FDA) approved BoNT in 1989, Oculinum was bought by Allergan in 1991, and Botox® was manufactured. After this, the FDA has approved BoNT for various cosmetic and non-cosmetic applications. Cosmetic applications for glabellar lines in 2002, severe axillary hyperhidrosis in 2004, migraines in 2010, lateral canthal lines in 2013, forehead lines in 2017 and sialorrhea in 2018 [9,26].The purpose of this review is to present an overview of BoNT and demonstrate the optimal, safe injection areas and effective dose for application of BoNT in the oral and maxillofacial area. This practical guideline depicts the anatomy of the facial muscles relative to the BoNT injection points and includes a narrative literature review.

2. Materials and Methods

This review explores quantitative data using a systematic search on studies depicting dose range and injection points from expert consensus opinions. A literature search was conducted using MEDLINE and PubMed electronic databases for the period from January 2002 to December 2022. Manual study searches were also performed using the reference list of articles included during the search process.
The inclusion criteria were as follows:
  • Studies in the English language;
  • Include dosage of BoNT and/or number of injection points;
  • Be performed in human adults with no diseases;
  • Given BoNT injection of the face for cosmetic or esthetic purpose;
  • The literature is limited to expert consensus.
Exclusion criteria were as follows:
  • Studies using BoNT for other reasons than cosmetic/aesthetic: i.e., stroke, neurogenic, bladder management, spasticity, sialorrhea, bruxism, strabismus, myofascial pain, TMJ, or obesity;
  • Studies using BoNT for cosmetic/aesthetic reasons in other parts of the body or other reasons: i.e., skin texture, scar, androgenic alopecia, neck wrinkles, trapezius hypertrophy, or calf hypertrophy;
  • Studies that investigated only a single muscle.
The search included the following keywords used in different combinations: “botox”, “botulinum toxin”, “consensus”, “aesthetic”, “cosmetic”, “systematic review”, and “face”. The term “botox consensus” retrieved 202 studies, “botulinum toxin” AND “consensus” retrieved 315 studies. The search term “face botulinum toxin consensus” resulted in 56 studies, “esthetic botulinum toxin” AND “consensus” resulted in 54 articles, and “cosmetic botulinum toxin consensus” resulted in 42 studies. The term “botox systematic review” retrieved 421 articles.

3. Results

Titles and abstracts were screened, the eligibility criteria were applied, and full text analysis was performed in relevant publications. Thirty-three full text articles were screened for eligibility, of which six were excluded because of a lack of BoNT dosages and type of paper. A total of 27 articles were included in the literature review. The injection dosage and points proposed in this paper are based on the findings from such various reviews.
The BoNT dose and injection points from the views of expert opinions are summarized in Table 1, Table 2 and Table 3. A total of 27 consensus articles were reviewed after retrieving the data through a systematic search. Of the 27 studies, 4 were specified towards Asians, and therefore organized into a separate table (Table 3) [27,28,29,30]. Of the 23 other studies, those by Fagien et al. [31] and by Bertossi et al. [32] were each separately updated by the same group and therefore were excluded from the summary. Carruthers et al. [33] updated their consensus in 2008 and again in 2013 [34,35]. The initial 2004 consensus was grouped with the 2008 consensus, but the 2013 consensus was summarized because of slightly different parameters. Studies by Raspaldo et al. [36] and Gassia et al. [37] were identical to the 2010 consensus from Raspaldo et al. [38,39] and excluded from the summary tables. Most of the studies used onabotulinumtoxinA units, but three studies using different units of abobotulinumtoxinA were excluded from the review [40,41,42]. Three other studies using different BoNTA were included. Studies by Sundaram et al. [28] and Yutskovskay et al. [43] used incobotulinumtoxinA, while Ahn et al. [27] utilized Medytox. A total of 16 consensus papers were summarized in this narrative review (Table 1, Table 2 and Table 3).

3.1. Cosmetic Indications and Contraindications

Elucidating the cosmetic indications and contraindications of BoNT is crucial to maximize patient satisfaction and minimize complications. Patients with dynamic wrinkles, which are formed during facial expression are indicated [4]. Areas with dynamic motion such as the glabella, forehead, peri-orbital lines, nasal rhytides, and perioral rhytides are common injection areas [7,54,55]. Patients with static wrinkles that are present at rest can also be candidates. However, the results are less dramatic and additional treatment sessions or additional esthetic procedures, such as fillers, may be required to achieve ideal outcomes. Excessive contraction of muscles or hyperactivity of specific muscles can also cause non-cosmetic appearances. Patients with bulky masseters, cobble stone chins, gummy smiles, asymmetric smiles, depressed mouth corners, brow ptosis, flaring nostrils, depressed nasal tips, temporal hypertrophy, and trapezius hypertrophy can achieve esthetic results by targeting the precise muscles [7,22]. Patients with hypertrophic submandibular glands and parotid glands can also benefit esthetically in select cases [56].
Contraindications include immunocompromised patients with neuromuscular disorders, such as myasthenia gravis and Lambert–Eaton syndrome; neurodegenerative diseases such as amyotrophic lateral sclerosis; and pregnancy and breast-feeding [4,19]. BoNT is also contraindicated in patients with unrealistic expectations, body dysmorphic syndrome, keloidal scarring, active dermatoses or infection in the treatment area, motor weakness in the treatment area (Bell’s palsy), and allergic reactions to BoNT constituents (cow’s milk protein allergy using abobotulinumtoxinA) [57]. Theoretical drug interactions between BoNT and aminoglycoside antibiotics, quinidine, calcium channel blocker, magnesium sulfate, succihylcholine, and polymyxin exist [22,58,59].

3.2. Cosmetically Used Botulinum Toxin Products

Currently, there are several popular FDA-approved (six BoNTA, one BoNTB) and non-approved toxin products on the market (Table 4) [8,12,60,61]. BoNTs vary in composition, complex size, molecular and chemical properties, supply form, and immunogenicity. Pure BoNT is manufactured as 150 kDa proteins that bind in different quantities to neurotoxin-associated complexing proteins (NAPs) to form high-molecular-weight progenitor complexes [8,62]. Commercial BoNT products have different complements of NAPs, which lead to the formation of various molecular weights and three-dimensional structures [62]. Excipients are added to ensure long-term storage and minimize inactive neurotoxins because they might not interact with nerve cells but are recognized by the immune system [63].

3.3. Facial Target Muscles and Injection Doses

Accurately administered injections and detailed knowledge of the anatomy to determine the correct depth and injection points are important factors for minimizing complications. The relevant anatomy including the muscles involved and amount of injection, is shown in Table 5 [20,28,44,55,60]. Thorough comprehension of the facial musculature and adjacent anatomy is essential before treatment initiation. Diffusion of BoNT differs according to the amount of mixed saline. However, in general, 1–5 mL of saline is mixed with 100 U of BoNTA, which results in diffusion distances 2.5–3 cm in diameter [4,20,64]. Before injection, good lighting, marking injection points, prefilling syringes with the required dose, and pre-photography are beneficial.

3.4. Injection Techniques of BoNT in the Face

BoNT injection depth and amounts differ within each area of the face. Intramuscular injections act on the neuromuscular end plate, leading to denervation of the muscles and subsequent relaxation [19]. Injections can be subdermal in areas where the muscles are very superficial, such as the orbicularis oculi and frontalis muscles. The maximum injection dosage should be injected into the muscle origin, where action is the strongest. Muscles with fibers inserted into the skin can be injected intradermally. Moreover, superficial fibers can be targeted subdermally [4].

3.4.1. Forehead Frontalis

Contraction of the frontalis muscle leads to wrinkles on the forehead. This muscle is the only elevator muscle of the upper face originating from the galeal aponeurotic and is inserted into the subcutaneous level and deep dermis of the skin on the superciliary arch. The forehead has high variability due to the diverse individualized animation patterns during facial expressions. The key is to leave the forehead with little activity without leaving a frozen look. Intracutaneous injection of 15–20 U should be targeted at least 1–2 cm above (higher in aged individuals) the orbital rim to prevent brow ptosis (Figure 1). Lateral injection points should extend 2 cm laterally from the eyebrow to minimize excessive lifting of the eyebrow that may lead to a “samurai” or “Spock” look [19,56]. The lateral border of the frontalis muscle is situated 1 cm lateral to the superior temporal crest, which is on the same perpendicular plane as the lateral eyebrow tail [65]. When the BoNT injection point is too medial, diffusion into the lateral portion of the frontalis muscle is difficult and may cause such a look.

3.4.2. Glabella

Wrinkles in this area are formed by continuous action of the procerus and corrugator supercilii muscles, which are brow depressors. They are formed as a result of frowning and may exist as static vertical lines if left untreated in the dynamic state. The corrugator supercilii originates from the medial supraorbital ridge, thickening and thinning laterally [55]. The muscle lies below the frontalis muscle and injections should be intramuscular and deep. The procerus muscle originates from the periosteum of the nasal bone and upper lateral cartilages, and inserts into the glabellar skin and fibers of the frontalis muscle [56].
In total, 12 U to 20 U of BoNT should be injected into 3 to 5 points (Figure 2). Three injection points are usually required in Asian women. Additionally, five-point injections are helpful in men or patients with bulkier glabellas [28]. The injection point for the procerus muscle should be marked at the intersection of the two lines drawn from the medial brow to the contralateral medial canthus. Injection into the corrugator supercilia is deeper in the medial part and slightly superficial on the lateral side. To avoid brow ptosis, injections should not pass through the mid-pupillary line. Injections should be 1 cm superior to the upper inner boundary of the orbital rim to minimize blepharoptosis. This occurs when toxin spreads to the levator palpebrae superioris muscle, making apparent disfigurement and movement of the eyes difficult. The needle should also point upward at a 30° angle [56,66].

3.4.3. Lateral Canthal Lines (Crow’s Feet)

Crow’s feet are caused by contraction of the superficially situated orbicularis oculi muscle. It is a sphincter muscle encircling the orbit and is divided into three portions: palpebral, orbital, and lacrimal [33]. The muscle originates from the nasal part of the frontal bone, the medial palpebral ligament, and the frontal process of the maxilla. The most peripheral preorbital part causes protrusion of the eyebrow and voluntary eye closure is the target of BoNT [67]. Wrinkles in this area can be seen starting in patients aged approximately 20–25 years old [19]. To minimize complications, 6 U to 12 U of BoNT per side should be injected intracutaneously, producing a wheal (Figure 3). Three injections should be targeted 1.5 cm lateral to the lateral canthus or 1 cm outside the bony orbital wall to reduce the chances of diplopia, ectropion, and drooping of the lower eyelid [33]. To prevent asymmetrical smiles, injections should not be targeted close to the inferior margin of the zygoma. This area is susceptible to bruising due to the high vascularity [35,49].

3.4.4. Infraorbital Rhytides

The palpebral part of the lower eyelid closes the eyelid and is subdivided into preseptal and pretarsal portions [49]. Subdermal injection of 2 U to 4 U of BoNT should be administered into the junction of the pretarsal and preseptal portions of the orbicularic oculi (Figure 4). To possess a “charming roll” in the pretarsal area, which makes the patient appear youthful, injections should be distanced from the lower ciliary margin [28]. Medial infraorbital BoNT injection doses should be minimal and injection delicate to prevent lower eyelid edema [28]. Patients with a positive snap test, lower eyelid puffiness, and previous lower lid blepharoplasty are not good candidates because scleral show may result in complications [49].

3.4.5. Bunny Lines

Bunny lines are created by contraction of the transverse nasalis muscle, which draws the nose up and medially [50]. Other muscles such as the procerus, levator labii superioris alaeque nasi (LLSAN), and medial fibers of the orbicularis oculi may also have minor contributions. Intramuscular BoNT injections of 3 U to 4 U should be performed slightly lateral to the mid nose bridge (Figure 5). A third medial injection on the bridge of the nose can be performed in severe cases [50]. Injections that are too lateral or inferior may lead to lip drooping if BoNT is diffused into the levator labii superioris (LLS), levator anguli oris, or LLSAN muscles [67].

3.4.6. Gummy Smile

A symmetrical smile with 1–2 mm gingival exposure is perceived as an esthetic smile [68,69]. Gummy smile is defined as an excessive gingival display greater than 3 mm when smiling. Mazzuco and Hexsel [70] further subclassified the gummy smile into four types: anterior, posterior, mixed, and asymmetric. In moderate gummy smile, the LLSAN elevates and everts the upper lip, while the depressor septi nasi muscle pulls the nasal tip down. In severe gummy smile, the LLS and to a lesser extent the zygomaticus minor (ZMi) also raise the upper lip. A single-point injection of 2 U on each side, 1 cm lateral to the nostril ala, also known as the Yonsei point, can target these three muscles (Figure 6) [56,71].

3.4.7. Perioral Rhytides

Dynamic vertical rhytides in this area are due to sphincter action of the orbicular oris muscle. The orbicularis oris originates from the modiolus, mandible, and the maxilla near the incisor fossa and inserts into the skin of lips encircling the upper and lower lips [67]. The treatment of vertical perioral wrinkles requires patient to contract the lips. Depending on anatomy, intracutaneous and intradermal injections can be administered. In total, 2–3 U of BoNT should be injected along the vermilion border (Figure 7). Flattening of the vermilion border can be a secondary complication due to contraction of the orbicularis oris. However, this can be easily corrected using dermal fillers. Since functional competency, facial asymmetry, lip depression, or lip elevation might occur, low doses of BoNT are recommended [44].

3.4.8. Masseter Hypertrophy

The masseter muscle is one of the four masticatory muscles that facilitates chewing and causes mouth closing. It is a superficial quadrangular muscle that originates from the zygomatic arch and attaches to the lateral border and the angle of the mandible [56]. Particularly in Asian women, a small oval face with a non-square angle and smooth jaw contour is perceived as esthetically appealing. Since hypertrophy of the masseter leads to a broad face, reduction in the muscle using BoNT has become a popular procedure in Asian countries.
Injections need to be both deep and superficial to effectively reduce the large muscle because a deep inferior tendon (DIT) can block diffusion into both levels, causing paradoxical masseteric bulging [65]. Typically, 25 U to 30 U of BoNT can be injected on each side of the masseter (Figure 8). Injection points can be modified in smaller muscles and skinnier patients to minimize diffusion of the toxin anteriorly, which may leave a “sunken cheek” appearance. Injection too anterior or superiorly can also cause “sunken cheek”. Deeply injecting below a line drawn from the mouth corner to the tragus and at least 1 cm away from the anterior border of the masseter muscle is advisable [72,73]. Injection into the masseter can also reduce bruxism, clenching, and myofascial pain symptoms. However excessive doses of BoNT may temporarily cause difficulty in chewing.

3.4.9. Parotid Gland Hypertrophy

The parotid gland is an inverted-pyramidal-shaped organ that lies on the posterior border of the mandible angle [56,74]. Due to congenital, iatrogenic, or acquired conditions, BoNT in the glands plays a role in the esthetically slimming volume of the hypertrophic glands. BoNT can block not only the acetylcholine from binding in the neuromuscular junction but also in the salivary gland [28,75]. Initially, BoNT was used to treat sialorrhea. However, injection to reduce benign hypertrophy of the salivary glands has also been reported [65]. When the mandibular contour is bulky and extends below the angle, parotid gland hypertrophy could be suspected. Since the parotid gland lies superficial to the masseter muscle, 20 U to 30 U of BoNT should be injected more superficially than the masseter (Figure 9) [28]. Since the majority of salivary production comes from the submandibular gland, high-dose injections simultaneously into both the parotid gland and submandibular gland in patients may lead to severe dry mouth [56,76,77].

3.4.10. Drooping Oral Commissures

The depressor anguli oris (DAO) muscle originates from the oblique line of the mandible and inserts into the modiolus [4,66]. Excessive contraction of the depressor anguli oris muscle pulls the mouth corners down creating a drooping and sad impression. Subdermally or intradermally 4 U to 10 U of BoNT can be injected, 1 cm lateral and lower to the mouth corner (Figure 10) [51]. In Asian patients, since the modiolus is situated in a lower position than in Caucasians, injection can be even lower [56]. Injection into the depressor labii inferior could cause difficulty in sipping water, while imprecise targeting of the muscles can lead to an asymmetrical smile.

3.4.11. Cobble Stone Chin

The mentalis muscle is a lower lip levator, which changes the chin texture when hyperactivated. This muscle originates from the alveolar bone inferior to the lateral incisor and attaches medially towards the skin, forming a dome-shaped chin [56]. A pebbled or dimpled appearance of the chin can be treated with two injections, totaling 10 U into the mentalis muscle (Figure 11). Injection too superiorly in proximity to the lower lip can spread BoNT to the orbicularis oris, and too laterally to the DAO. BoNT diffusion into both muscles may lead to ptosis or asymmetry of the lower lip [51]. It is important to remain at least 1 cm below the mental sulcus to avoid oral incompetence [55].

3.5. Ultrasonography (US)-Guided Botulinum Toxin Techniques

To maximize accuracy and minimize complications, US-guided treatments have been actively utilized in minimally invasive esthetic treatments, such as BoNT, fillers, and threads [65,78,79]. US is useful for distinguishing between anatomical structures such as vessels, muscle, fat, bone, and glands [66]. Not only can anatomical landmarks be seen in real time, but also injection needles and cannulas can be visualized during the procedures, which make outcomes more predictable (Figure 12). Therapy can be reproducible, which increases the efficacy and safety of esthetic treatments. Rather than injecting blindly into a muscle or layer, BoNT can accurately target a selected area and thereby treat the asymmetry in patients with crooked smiles or even deviated lower faces [80,81].

3.6. Complications

BoNT is generally considered to have a wide safety margin in terms of risk. However, since its use has become more common, various injection-related adverse effects (AE) have arisen. Complications are usually technique-dependent, and their incidence decreases as the injector becomes experienced [57]. Complications are the result of reactions to the injection itself or due to the spread of BoNT to untargeted areas [57,82]. Injection-related reactions, such as erythema, edema, and injection pain, are usually mild and temporary and resolve within days. Bruising and ecchymosis are common but tend to take longer to resolve. A recent systematic review reported complication rates in the upper face to be 16% [83]. Headaches and migraines were the most frequently reported AE and this may be related to periosteal trauma or intramuscular hematoma formation during injection [83,84]. Anxiety, vasovagal episodes, paresthesia or dysesthesia, and allergic reactions should also be closely monitored [4,57]. Undesired effects due to the distant spread of BoNT include blepharoptosis, eyebrow ptosis, undesired eyebrow shape, unnatural face, eye opening difficulty, and unsatisfactory results [73,85]. Temporary blepharoptosis is seen in approximately 1–5% of patients [4]. Nasopharyngitis, sinusitis, blurred vision, upset stomach, voice changes, restricted mouth opening, muscle atrophy, and stiffness were also adverse events (AEs) encountered after injection [9,22,84].
The development of neutralizing antibodies is a crucial AE. BoNT may be regarded as a foreign substance in the body that induces an immune response after repeated treatment [86]. Therefore, to reduce antigen occurrence, a commercial product with a low risk of antigenicity should be selected, such as that with fewer complex proteins. Another way to minimize the risk of neutralizing antibody formation is to use the minimum dose needed for effect, injected at least 3 months apart, and avoid booster injections within one month [87,88].

4. Discussion

Several expert consensus statements have also been published from various parts of the world including Europe, Pan-Asia, and the Americas [28,33,34,35,38,44,45,46,47,48,49,50,51,52,53]. The results are shown in Table 1, Table 2 and Table 3 and in the supplementary table (Table S1). There are also numerous systematic reviews related to dosing and effective injections of BoNT. A Cochrane systematic review by Camargo et al. [54] in 2021 looked at 14,919 people (mostly women) from 65 RCTs to see if BoNTA was safe and effective in facial wrinkles. Different types of BoNT were compared with a placebo or each other in cases where glabellar lines, crow’s feet, perioral lines, and forehead lines were treated. The study found that at 4 weeks after injection, all types of BoNT reduced glabellar lines more than the placebo. Regarding safety, ptosis was the only major AE reported and it was seen in fewer than 5% of the trials [54]. The dose range according to the facial region and BoNT brand was also investigated. The dose for glabella lines using onabotulinumtoxinA was 8 U to 80 U, abobotulinumtoxinA was 20 U to 75 U, incobotulinumtoxinA was 20 U to 24 U, daxibotulinumtoxinA was 20 U to 60 U, NewBoNTA (Medytox®, Prostigne®, Neuronox®) was 20 U, LiquidBoNTA was 20 U to 75 U, and prabotulinumtoxinA was 20 U to 60 U [89,90,91]. The dose for forehead lines using onabotulinumtoxinA was 10 U to 48 U, and incobotulinumtoxinA was 10 U to 20 U [92,93]. For crow’s feet the dose using onabotulinumtoxinA was 7.5 U to 24 U, abobotulinumtoxinA was 30 U, incobotulinumtoxinA was 7.5 U to 12 U, and Neuronox® was 24 U [90,94]. Perioral lines were treated with 7.5 U to 12 U of onabotulinumtoxinA [95,96]. The distribution of injection points for the glabellar lines were three to seven points. It was four to eight for the forehead, three points for the crow’s feet, and four points for the perioral lines. The dose and injection areas seem to differ for all types of BoNTAs for each area. Some BoNTA types have similar efficacy, but some areas require more Units for similar effect. Still, the data comparing different types of BoNT are limited, and with the evolution of newer BoNT brands, further investigation is needed to find the accurate efficacy and dose.
The injections points vary slightly between culture and ethnicity, and with sex. In general, men need greater amounts of BoNT injection because they tend to have thicker skin, more facial movement, and larger and stronger muscles [97]. Injection doses for the masseter muscle are higher in the Asian population, and this may be due to slightly different standards of beauty, with Asians preferring a slimmer jaw line [27]. Since most of the AEs occur when higher doses have been injected, it is important to comprehend the adequate technique [54,56]. One interesting finding is that parotid gland hypertrophy injections for cosmetic reasons have only recently been reported in a consensus for Asians [28]. The treatment itself may be preferred in Asian countries where a bulky jaw is perceived as less attractive, and this can be caused by either a hypertrophic masseter muscle or hypertrophic parotid gland. The indications for BoNT are broadening in both esthetical and therapeutical fields. This may be due to adjunctive tools, such as US, that help in precise injection and monitoring of subsequent changes [65]. To date, BoNT has shown promising treatment modalities in many fields, and further research will render more accurate injection techniques and versatile applications.

5. Concluding Remarks

There has been a global rise in the demand for non-invasive procedures to help patients rejuvenate and appear youthful. BoNT is now the most performed esthetic procedure in the world with various types of BoNT that have different properties out in the market. More practitioners are using BoNT and demand appropriate guidelines so that injections using BoNT can be performed safely and effectively for the treatment of dynamic rhytides and hypertrophic structures. This paper is a narrative review of the consensus statements of expert practitioners and the various literature on the injection points and techniques, highlighting both the Asian and Caucasian population separately. This paper can serve as a practical illustrative guide and reference for optimal, safe injection areas and effective doses for application of BoNT in the face and oral and maxillofacial area. One limitation of this study was that a single author extracted the data and a systematic meta-analysis was not performed, and therefore the risk of bias was not investigated. Larger consensus statements and dose-ranging systematic studies comparing female to male, Caucasian to Asian, and younger to older patients should be conducted in the future.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/toxins15020082/s1, Table S1. List of 27 consensus recommendation papers retrieved for the literature review.

Funding

This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP; Ministry of Science, ICT & Future Planning) (No. 2017R1C1B5018358) and by the Korea government (MSIT; Ministry of Science and ICT) (No. 2021R1F1A1049784).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Written informed consent was obtained from the patient to publish this paper.

Data Availability Statement

Not applicable.

Acknowledgments

The authors would like to thank Kyung Jun Park for his medical expertise and Byoung-Ae Kim for her technical assistance.

Conflicts of Interest

The author declares no conflict of interest.

Abbreviations

AEAdverse effects
BoNTBotulinum toxin
CSMCorrugator supercilia muscle
DAODepressor anguli oris
DLIDepressor labii inferioris
FMFrontalis muscle
HASHuman Serum Albumin
IMIntramuscularly
UInternational Unit
IVIntravenously
LLiquid
LLSLevator labii superioris
LLSANLevator labii superioris alaeque nasi
NACLSodium chloride
NAPsNeurotoxin-associated complexing proteins
OOcOrbicularis oculi
OOrOrbicularis oris
PPowder
POOrally
q.s.Quantum sufficit
USUltrasonography
ZmiZygomaticus minor
ZMjZygomaticus major
IPInjection points
nNumber
FFemale
MMale
UpUpper
LLower
NRNot reported

References

  1. Liew, S.; Dart, A. Nonsurgical reshaping of the lower face. Aesthet. Surg. J. 2008, 28, 251–257. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  2. Swift, A.; Remington, K. BeautiPHIcation™: A global approach to facial beauty. Clin. Plast. Surg. 2011, 38, 347–377. [Google Scholar] [CrossRef]
  3. Liew, S.; Wu, W.T.; Chan, H.H.; Ho, W.W.; Kim, H.J.; Goodman, G.J.; Peng, P.H.; Rogers, J.D. Consensus on changing trends, attitudes, and concepts of Asian beauty. Aesthet. Plast. Surg. 2016, 40, 193–201. [Google Scholar] [CrossRef] [Green Version]
  4. Small, R. Botulinum toxin injection for facial wrinkles. Am. Fam. Physician 2014, 90, 168–175. [Google Scholar] [PubMed]
  5. Zimbler, M.S.; Kokoska, M.S.; Thomas, J.R. Anatomy and pathophysiology of facial aging. Facial Plast. Surg. Clin. N. Am. 2001, 9, 179–187. [Google Scholar]
  6. Gadhia, K.; Walmsley, A.D. Facial aesthetics: Is botulinum toxin treatment effective and safe? A systematic review of randomised controlled trials. Br. Dent. J. 2009, 207, E9; discussion 216–217. [Google Scholar] [CrossRef]
  7. Phan, K.; Younessi, S.; Dubin, D.; Lin, M.J.; Khorasani, H. Emerging off-label esthetic uses of botulinum toxin in dermatology. Dermatol. Ther. 2022, 35, e15205. [Google Scholar] [CrossRef]
  8. Frevert, J. Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products. Drugs R D 2015, 15, 1–9. [Google Scholar] [CrossRef] [Green Version]
  9. Alster, T.S.; Harrison, I.S. Alternative clinical indications of botulinum toxin. Am. J. Clin. Derm. 2020, 21, 855–880. [Google Scholar] [CrossRef]
  10. Serrera-Figallo, M.A.; Ruiz-de-León-Hernández, G.; Torres-Lagares, D.; Castro-Araya, A.; Torres-Ferrerosa, O.; Hernández-Pacheco, E.; Gutierrez-Perez, J.L. Use of Botulinum Toxin in Orofacial Clinical Practice. Toxins 2020, 12, 112. [Google Scholar] [CrossRef] [Green Version]
  11. Jankovic, J. Botulinum toxin: State of the art. Mov. Disord. 2017, 32, 1131–1138. [Google Scholar] [CrossRef] [PubMed]
  12. Benecke, R. Clinical relevance of botulinum toxin immunogenicity. BioDrugs 2012, 26, e1–e9. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  13. Arnon, S.S.; Schechter, R.; Inglesby, T.V.; Henderson, D.A.; Bartlett, J.G.; Ascher, M.S.; Eitzen, E.; Fine, A.D.; Hauer, J.; Layton, M.; et al. Botulinum toxin as a biological weapon: Medical and public health management. JAMA 2001, 285, 1059–1070. [Google Scholar] [CrossRef]
  14. Rosales, R.L.; Bigalke, H.; Dressler, D. Pharmacology of botulinum toxin: Differences between type A preparations. Eur. J. Neurol. 2006, 13 (Suppl. S1), 2–10. [Google Scholar] [CrossRef] [PubMed]
  15. Choudhury, S.; Baker, M.R.; Chatterjee, S.; Kumar, H. Botulinum Toxin: An Update on Pharmacology and Newer Products in Development. Toxins 2021, 13, 58. [Google Scholar] [CrossRef] [PubMed]
  16. Zhang, S.; Masuyer, G.; Zhang, J.; Shen, Y.; Lundin, D.; Henriksson, L.; Miyashita, S.I.; Martínez-Carranza, M.; Dong, M.; Stenmark, P. Identification and characterization of a novel botulinum neurotoxin. Nat. Commun. 2017, 8, 14130. [Google Scholar] [CrossRef] [PubMed]
  17. Carruthers, A.; Carruthers, J. Botulinum toxin type A. J. Am. Acad. Derm. 2005, 53, 284–290. [Google Scholar] [CrossRef] [PubMed]
  18. Rao, A.K.; Sobel, J.; Chatham-Stephens, K.; Luquez, C. Clinical guidelines for diagnosis and treatment of botulism, 2021. MMWR Recomm. Rep. 2021, 70, 1–30. [Google Scholar] [CrossRef] [PubMed]
  19. Jaspers, G.W.; Pijpe, J.; Jansma, J. The use of botulinum toxin type A in cosmetic facial procedures. Int. J. Oral Maxillofac. Surg. 2011, 40, 127–133. [Google Scholar] [CrossRef] [PubMed]
  20. Kwon, K.H.; Shin, K.S.; Yeon, S.H.; Kwon, D.G. Application of botulinum toxin in maxillofacial field: Part I. Bruxism and square jaw. Maxillofac. Plast. Reconstr. Surg. 2019, 41, 38. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  21. Chang, C.S.; Bergeron, L.; Yu, C.C.; Chen, P.K.; Chen, Y.R. Mandible changes evaluated by computed tomography following Botulinum Toxin A injections in square-faced patients. Aesthet. Plast. Surg. 2011, 35, 452–455. [Google Scholar] [CrossRef] [PubMed]
  22. Majid, O.W. Clinical use of botulinum toxins in oral and maxillofacial surgery. Int. J. Oral Maxillofac. Surg. 2010, 39, 197–207. [Google Scholar] [CrossRef] [PubMed]
  23. Schantz, E.J.; Johnson, E.A. Properties and use of botulinum toxin and other microbial neurotoxins in medicine. Microbiol. Rev. 1992, 56, 80–99. [Google Scholar] [CrossRef] [PubMed]
  24. Scott, A.B. Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 1980, 87, 1044–1049. [Google Scholar] [CrossRef]
  25. Carruthers, J.; Carruthers, A. Botulinum toxin in facial rejuvenation: An update. Derm. Clin. 2009, 27, 417–425. [Google Scholar] [CrossRef]
  26. Muñoz Lora, V.R.M.; Del Bel Cury, A.A.; Jabbari, B.; Lacković, Z. Botulinum toxin type A in dental medicine. J. Dent. Res. 2019, 98, 1450–1457. [Google Scholar] [CrossRef]
  27. Ahn, B.K.; Kim, Y.S.; Kim, H.J.; Rho, N.K.; Kim, H.S. Consensus recommendations on the aesthetic usage of botulinum toxin type A in Asians. Derm. Surg. 2013, 39, 1843–1860. [Google Scholar] [CrossRef]
  28. Sundaram, H.; Huang, P.H.; Hsu, N.J.; Huh, C.H.; Wu, W.T.; Wu, Y.; Cassuto, D.; Kerscher, M.J.; Seo, K.K. Aesthetic applications of botulinum toxin A in Asians: An international, multidisciplinary, Pan-Asian consensus. Plast. Reconstr. Surg. Glob. Open 2016, 4, e872. [Google Scholar] [CrossRef]
  29. Kapoor, K.M.; Chatrath, V.; Anand, C.; Shetty, R.; Chhabra, C.; Singh, K.; Vedamurthy, M.; Pai, J.; Sthalekar, B.; Sheth, R. Consensus recommendations for treatment strategies in Indians using botulinum toxin and Hyaluronic Acid fillers. Plast. Reconstr. Surg. Glob. Open 2017, 5, e1574. [Google Scholar] [CrossRef] [Green Version]
  30. Wu, W.T.; Liew, S.; Chan, H.H.; Ho, W.W.; Supapannachart, N.; Lee, H.K.; Prasetyo, A.; Yu, J.N.; Rogers, J.D. Consensus on current injectable treatment strategies in the Asian face. Aesthet. Plast. Surg. 2016, 40, 202–214. [Google Scholar] [CrossRef] [Green Version]
  31. Fagien, S.; Raspaldo, H. Facial rejuvenation with botulinum neurotoxin: An anatomical and experiential perspective. J. Cosmet. Laser Ther. 2007, 9 (Suppl. S1), 23–31. [Google Scholar] [CrossRef] [PubMed]
  32. Bertossi, D.; Cavallini, M.; Cirillo, P.; Piero Fundarò, S.; Quartucci, S.; Sciuto, C.; Tonini, D.; Trocchi, G.; Signorini, M. Italian consensus report on the aesthetic use of onabotulinum toxin A. J. Cosmet. Derm. 2018, 17, 719–730. [Google Scholar] [CrossRef] [PubMed]
  33. Carruthers, J.; Fagien, S.; Matarasso, S.L. Consensus recommendations on the use of botulinum toxin type a in facial aesthetics. Plast. Reconstr. Surg. 2004, 114 (Suppl. S6), 1s–22s. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  34. Carruthers, J.D.A.; Glogau, R.G.; Blitzer, A. Advances in facial rejuvenation: Botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies—Consensus recommendations. Plast. Reconstr. Surg. 2008, 121 (Suppl. S5), 5s–30s. [Google Scholar] [CrossRef] [PubMed]
  35. Carruthers, J.; Fournier, N.; Kerscher, M.; Ruiz-Avila, J.; Trindade de Almeida, A.R.; Kaeuper, G. The convergence of medicine and neurotoxins: A focus on botulinum toxin type A and its application in aesthetic medicine—A global, evidence-based botulinum toxin consensus education initiative: Part II: Incorporating botulinum toxin into aesthetic clinical practice. Dermatol. Surg. 2013, 39 Pt 2, 510–525. [Google Scholar]
  36. Raspaldo, H.; Gassia, V.; Niforos, F.R.; Michaud, T. Global, 3-dimensional approach to natural rejuvenation: Part 1—Recommendations for volume restoration and the periocular area. J. Cosmet. Derm. 2012, 11, 279–289. [Google Scholar] [CrossRef]
  37. Gassia, V.; Raspaldo, H.; Niforos, F.R.; Michaud, T. Global 3-dimensional approach to natural rejuvenation: Recommendations for perioral, nose, and ear rejuvenation. J. Cosmet. Derm. 2013, 12, 123–136. [Google Scholar] [CrossRef]
  38. Raspaldo, H.; Niforos, F.R.; Gassia, V.; Dallara, J.M.; Bellity, P.; Baspeyras, M.; Belhaouari, L.; Group, C. Lower-face and neck antiaging treatment and prevention using onabotulinumtoxin A: The 2010 multidisciplinary French consensus—Part 2. J. Cosmet. Dermatol. 2011, 10, 131–149. [Google Scholar] [CrossRef]
  39. Raspaldo, H.; Baspeyras, M.; Bellity, P.; Dallara, J.M.; Gassia, V.; Niforos, F.R.; Belhaouari, L. Upper- and mid-face anti-aging treatment and prevention using onabotulinumtoxin A: The 2010 multidisciplinary French consensus—Part 1. J. Cosmet. Dermatol. 2011, 10, 36–50. [Google Scholar] [CrossRef]
  40. Ascher, B.; Talarico, S.; Cassuto, D.; Escobar, S.; Hexsel, D.; Jaén, P.; Monheit, G.D.; Rzany, B.; Viel, M. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)—Part II: Wrinkles on the middle and lower face, neck and chest. J. Eur. Acad. Derm. Venereol. 2010, 24, 1285–1295. [Google Scholar] [CrossRef]
  41. Kane, M.; Donofrio, L.; Ascher, B.; Hexsel, D.; Monheit, G.; Rzany, B.; Weiss, R. Expanding the use of neurotoxins in facial aesthetics: A consensus panel’s assessment and recommendations. J. Drugs Derm. 2010, 9 (Suppl. S1), s7–s22, quiz s23–s25. [Google Scholar]
  42. Ascher, B.; Talarico, S.; Cassuto, D.; Escobar, S.; Hexsel, D.; Jaén, P.; Monheit, G.D.; Rzany, B.; Viel, M. International consensus recommendations on the aesthetic usage of botulinum toxin type A (Speywood Unit)—Part I: Upper facial wrinkles. J. Eur. Acad. Derm. Venereol. 2010, 24, 1278–1284. [Google Scholar] [CrossRef] [PubMed]
  43. Yutskovskaya, Y.; Gubanova, E.; Khrustaleva, I.; Atamanov, V.; Saybel, A.; Parsagashvili, E.; Dmitrieva, I.; Sanchez, E.; Lapatina, N.; Korolkova, T.; et al. IncobotulinumtoxinA in aesthetics: Russian multidisciplinary expert consensus recommendations. Clin. Cosmet. Investig. Derm. 2015, 8, 297–306. [Google Scholar]
  44. Maas, C.; Kane, M.A.; Bucay, V.W.; Allen, S.; Applebaum, D.J.; Baumann, L.; Cox, S.E.; Few, J.W.; Joseph, J.H.; Lorenc, Z.P.; et al. Current aesthetic use of abobotulinumtoxinA in clinical practice: An evidence-based consensus review. Aesthet. Surg. J. 2012, 32 (Suppl. S1), 8s–29s. [Google Scholar] [CrossRef]
  45. Imhof, M.; Podda, M.; Sommer, B. S1 guideline aesthetic botulinum toxin therapy. J. Dtsch. Derm. Ges. 2013, 11, e1–e13. [Google Scholar] [CrossRef]
  46. Lorenc, Z.P.; Kenkel, J.M.; Fagien, S.; Hirmand, H.; Nestor, M.S.; Sclafani, A.P.; Sykes, J.M.; Waldorf, H.A. Consensus panel’s assessment and recommendations on the use of 3 botulinum toxin type A products in facial aesthetics. Aesthet. Surg. J. 2013, 33 (Suppl. S1), 35s–40s. [Google Scholar]
  47. Sundaram, H.; Signorini, M.; Liew, S.; Trindade de Almeida, A.R.; Wu, Y.; Vieira Braz, A.; Fagien, S.; Goodman, G.J.; Monheit, G.; Raspaldo, H. Global Aesthetics Consensus: Botulinum Toxin Type A—Evidence-Based Review, Emerging Concepts, and Consensus Recommendations for Aesthetic Use, Including Updates on Complications. Plast. Reconstr. Surg. 2016, 137, 518e–529e. [Google Scholar] [CrossRef] [Green Version]
  48. Sundaram, H.; Liew, S.; Signorini, M.; Vieira Braz, A.; Fagien, S.; Swift, A.; De Boulle, K.L.; Raspaldo, H.; Trindade de Almeida, A.R.; Monheit, G. Global aesthetics consensus: Hyaluronic Acid billers and botulinum toxin type A-recommendations for combined treatment and optimizing outcomes in diverse patient populations. Plast. Reconstr. Surg. 2016, 137, 1410–1423. [Google Scholar] [CrossRef] [Green Version]
  49. De Maio, M.; Swift, A.; Signorini, M.; Fagien, S. Facial assessment and injection guide for botulinum toxin and injectable Hyaluronic Acid fillers: Focus on the upper Face. Plast. Reconstr. Surg. 2017, 140, 265e–276e. [Google Scholar] [CrossRef]
  50. De Maio, M.; DeBoulle, K.; Braz, A.; Rohrich, R.J. Facial Assessment and Injection Guide for Botulinum toxin and injectable Hyaluronic Acid fillers: Focus on the midface. Plast. Reconstr. Surg. 2017, 140, 540e–550e. [Google Scholar] [CrossRef]
  51. De Maio, M.; Wu, W.T.L.; Goodman, G.J.; Monheit, G. Facial assessment and injection guide for botulinum toxin and injectable Hyaluronic Acid fillers: Focus on the lower face. Plast. Reconstr. Surg. 2017, 140, 393e–404e. [Google Scholar] [CrossRef] [PubMed]
  52. Kaminer, M.S.; Cox, S.E.; Fagien, S.; Kaufman, J.; Lupo, M.P.; Shamban, A. Re-examining the optimal use of neuromodulators and the changing landscape: A consensus panel update. J. Drugs Derm. 2020, 19, s5–s15. [Google Scholar]
  53. Signorini, M.; Piero Fundarò, S.; Bertossi, D.; Cavallini, M.; Cirillo, P.; Natuzzi, G.; Quartucci, S.; Sciuto, C.; Patalano, M.; Trocchi, G. OnabotulinumtoxinA from lines to facial reshaping: A new Italian consensus report. J. Cosmet. Derm. 2022, 21, 550–563. [Google Scholar] [CrossRef] [PubMed]
  54. Camargo, C.P.; Xia, J.; Costa, C.S.; Gemperli, R.; Tatini, M.D.; Bulsara, M.K.; Riera, R. Botulinum toxin type A for facial wrinkles. Cochrane Database Syst. Rev. 2021, 7, 011301. [Google Scholar]
  55. Janes, L.E.; Connor, L.M.; Moradi, A.; Alghoul, M. Current use of cosmetic toxins to improve facial aesthetics. Plast. Reconstr. Surg. 2021, 147, 644e–657e. [Google Scholar] [CrossRef]
  56. Kim, H.-J.; Seo, K.K.; Lee, H.-K.; Kim, J. Clinical anatomy for botulinum toxin injection. In Clinical Anatomy of the Face for Filler and Botulinum Toxin Injection; Springer: Singapore, 2016; pp. 55–92. [Google Scholar]
  57. Klein, A.W. Complications, adverse reactions, and insights with the use of botulinum toxin. Derm. Surg. 2003, 29, 549–556. [Google Scholar]
  58. Kwon, K.H.; Shin, K.S.; Yeon, S.H.; Kwon, D.G. Application of botulinum toxin in maxillofacial field: Part II. Wrinkle, intraoral ulcer, and cranio-maxillofacial pain. Maxillofac. Plast. Reconstr. Surg. 2019, 41, 42. [Google Scholar] [CrossRef]
  59. Pirazzini, M.; Rossetto, O.; Eleopra, R.; Montecucco, C. Botulinum Neurotoxins: Biology, Pharmacology, and Toxicology. Pharm. Rev. 2017, 69, 200–235. [Google Scholar] [CrossRef]
  60. Frevert, J.; Ahn, K.Y.; Park, M.Y.; Sunga, O. Comparison of botulinum neurotoxin type A formulations in Asia. Clin. Cosmet. Investig. Dermatol. 2018, 11, 327–331. [Google Scholar] [CrossRef] [Green Version]
  61. Solish, N.; Carruthers, J.; Kaufman, J.; Rubio, R.G.; Gross, T.M.; Gallagher, C.J. Overview of DaxibotulinumtoxinA for injection: A novel formulation of botulinum toxin type A. Drugs 2021, 81, 2091–2101. [Google Scholar] [CrossRef]
  62. Inoue, K.; Fujinaga, Y.; Watanabe, T.; Ohyama, T.; Takeshi, K.; Moriishi, K.; Nakajima, H.; Inoue, K.; Oguma, K. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. 1996, 64, 1589–1594. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  63. Goodnough, M.C.; Johnson, E.A. Stabilization of botulinum toxin type A during lyophilization. Appl. Environ. Microbiol. 1992, 58, 3426–3428. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  64. Dover, J.S.; Monheit, G.; Greener, M.; Pickett, A. Botulinum toxin in aesthetic medicine: Myths and realities. Dermatol. Surg. 2018, 44, 249–260. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  65. Kim, H.-J.; Youn, K.-H.; Kim, J.-S.; Kim, Y.S.; Hong, S.O.; Na, J. US applications in botulinum toxin injection procedures. In Ultrasonographic Anatomy of the Face and Neck for Minimally Invasive Procedures: An Anatomic Guideline for Ultrasonographic-Guided Procedures; Springer: Singapore, 2021; pp. 215–241. [Google Scholar]
  66. Kim, H.-J.; Youn, K.-H.; Kim, J.-S.; Kim, Y.S.; Hong, S.O.; Na, J. General US anatomy of the face and neck. In Ultrasonographic Anatomy of the Face and Neck for Minimally Invasive Procedures: An Anatomic Guideline for Ultrasonographic-Guided Procedures; Springer: Singapore, 2021; pp. 25–73. [Google Scholar]
  67. Gart, M.S.; Gutowski, K.A. Overview of botulinum toxins for aesthetic uses. Clin. Plast. Surg. 2016, 43, 459–471. [Google Scholar] [CrossRef]
  68. Kokich, V.O.; Kokich, V.G.; Kiyak, H.A. Perceptions of dental professionals and laypersons to altered dental esthetics: Asymmetric and symmetric situations. Am. J. Orthod. Dentofac. Orthop. 2006, 130, 141–151. [Google Scholar] [CrossRef] [PubMed]
  69. Hong, S.O.; Baek, S.H.; Choi, J.Y. Physical therapy for smile improvement after orthognathic Surgery. J. Craniofac. Surg. 2017, 28, 422–426. [Google Scholar] [CrossRef]
  70. Mazzuco, R.; Hexsel, D. Gummy smile and botulinum toxin: A new approach based on the gingival exposure area. J. Am. Acad. Derm. 2010, 63, 1042–1051. [Google Scholar] [CrossRef]
  71. Hwang, W.S.; Hur, M.S.; Hu, K.S.; Song, W.C.; Koh, K.S.; Baik, H.S.; Kim, S.T.; Kim, H.J.; Lee, K.J. Surface anatomy of the lip elevator muscles for the treatment of gummy smile using botulinum toxin. Angle Orthod. 2009, 79, 70–77. [Google Scholar] [CrossRef] [PubMed]
  72. Kundu, N.; Kothari, R.; Shah, N.; Sandhu, S.; Tripathy, D.M.; Galadari, H.; Gold, M.H.; Goldman, M.P.; Kassir, M.; Schepler, H.; et al. Efficacy of botulinum toxin in masseter muscle hypertrophy for lower face contouring. J. Cosmet. Derm. 2022, 21, 1849–1856. [Google Scholar] [CrossRef] [PubMed]
  73. Kroumpouzos, G.; Kassir, M.; Gupta, M.; Patil, A.; Goldust, M. Complications of botulinum toxin, A. An update review. J. Cosmet. Derm. 2021, 20, 1585–1590. [Google Scholar] [CrossRef]
  74. Park, H.J.; Hong, S.O.; Kim, H.M.; Oh, W.; Kim, H.J. Positional deformation of the parotid gland: Application to minimally invasive procedures. Clin. Anat. 2022, 35, 1147–1151. [Google Scholar] [CrossRef] [PubMed]
  75. Teymoortash, A.; Sommer, F.; Mandic, R.; Schulz, S.; Bette, M.; Aumüller, G.; Werner, J.A. Intraglandular application of botulinum toxin leads to structural and functional changes in rat acinar cells. Br. J. Pharm. 2007, 152, 161–167. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  76. Ondo, W.G.; Hunter, C.; Moore, W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson’s disease. Neurology 2004, 62, 37–40. [Google Scholar] [CrossRef] [PubMed]
  77. Jackson, C.E.; Gronseth, G.; Rosenfeld, J.; Barohn, R.J.; Dubinsky, R.; Simpson, C.B.; McVey, A.; Kittrell, P.P.; King, R.; Herbelin, L. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009, 39, 137–143. [Google Scholar] [CrossRef]
  78. Kim, H.-J.; Youn, K.-H.; Kim, J.-S.; Kim, Y.S.; Hong, S.O.; Na, J. US Applications in filler injection procedures. In Ultrasonographic Anatomy of the Face and Neck for Minimally Invasive Procedures: An Anatomic Guideline for Ultrasonographic-Guided Procedures; Springer: Singapore, 2021; pp. 243–264. [Google Scholar]
  79. Kim, H.-J.; Youn, K.-H.; Kim, J.-S.; Kim, Y.S.; Hong, S.O.; Na, J. US applications in thread lifting procedures. In Ultrasonographic Anatomy of the Face and Neck for Minimally Invasive Procedures: An Anatomic Guideline for Ultrasonographic-Guided Procedures; Springer: Singapore, 2021; pp. 265–274. [Google Scholar]
  80. Lee, H.J.; Kim, J.S.; Youn, K.H.; Lee, J.; Kim, H.J. Ultras.sound-guided botulinum neurotoxin type A injection for correcting asymmetrical smiles. Aesthet. Surg. J. 2018, 38, 130–134. [Google Scholar] [CrossRef] [Green Version]
  81. Kim, D.; Park, J.H.; Favero, V.; Mah, J.; Jung, Y.S.; Kim, S.T. Effect of botulinum toxin injection on asymmetric lower face with chin deviation. Toxins 2020, 12, 456. [Google Scholar] [CrossRef]
  82. Wollina, U.; Konrad, H. Managing adverse events associated with botulinum toxin type A: A focus on cosmetic procedures. Am. J. Clin. Derm. 2005, 6, 141–150. [Google Scholar] [CrossRef]
  83. Zargaran, D.; Zoller, F.; Zargaran, A.; Rahman, E.; Woollard, A.; Weyrich, T.; Mosahebi, A. Complications of cosmetic botulinum toxin A injections to the upper face: A systematic review and meta-analysis. Aesthet. Surg. J. 2022, 42, 327–336. [Google Scholar] [CrossRef]
  84. Sethi, N.; Singh, S.; DeBoulle, K.; Rahman, E. A review of Complications due to the use of botulinum toxin A for cosmetic indications. Aesthet. Plast. Surg. 2021, 45, 1210–1220. [Google Scholar] [CrossRef]
  85. Galadari, H.; Galadari, I.; Smit, R.; Prygova, I.; Redaelli, A. Use of AbobotulinumtoxinA for cosmetic treatments in the neck, and middle and lower areas of the face: A systematic review. Toxins 2021, 13, 169. [Google Scholar] [CrossRef]
  86. Wang, L.; Sun, Y.; Yang, W.; Lindo, P.; Singh, B.R. Type A botulinum neurotoxin complex proteins differentially modulate host response of neuronal cells. Toxicon 2014, 82, 52–60. [Google Scholar] [CrossRef] [Green Version]
  87. Wee, S.Y.; Park, E.S. Immunogenicity of botulinum toxin. Arch. Plast. Surg. 2022, 49, 12–18. [Google Scholar] [CrossRef] [PubMed]
  88. Albrecht, P.; Jansen, A.; Lee, J.I.; Moll, M.; Ringelstein, M.; Rosenthal, D.; Bigalke, H.; Aktas, O.; Hartung, H.P.; Hefter, H. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019, 92, e48–e54. [Google Scholar] [CrossRef] [PubMed]
  89. Wu, Y.; Wang, G.; Li, C.; Mao, C.; Lei, X.; Lee, E. Safety and Efficacy of OnabotulinumtoxinA for Treatment of Crow’s Feet Lines in Chinese Subjects. Plast. Reconstr. Surg. Glob. Open 2019, 7, e2079. [Google Scholar] [CrossRef] [PubMed]
  90. Moers-Carpi, M.; Dirschka, T.; Feller-Heppt, G.; Hilton, S.; Hoffmann, K.; Philipp-Dormston, W.G.; Rütter, A.; Tan, K.; Chapman, M.A.; Fulford-Smith, A. A randomised, double-blind comparison of 20 units of onabotulinumtoxinA with 30 units of incobotulinumtoxinA for glabellar lines. J. Cosmet. Laser Ther. 2012, 14, 296–303. [Google Scholar] [CrossRef] [PubMed]
  91. Ascher, B.; Kestemont, P.; Boineau, D.; Bodokh, I.; Stein, A.; Heckmann, M.; Dendorfer, M.; Pavicic, T.; Volteau, M.; Tse, A.; et al. Liquid formulation of AbobotulinumtoxinA exhibits a favorable efficacy and safety profile in moderate to severe glabellar Lines: A randomized, double-blind, placebo- and active comparator-controlled trial. Aesthet. Surg. J. 2018, 38, 183–191. [Google Scholar] [CrossRef] [Green Version]
  92. Carruthers, A.; Carruthers, J. A single-center, dose-comparison, pilot study of botulinum neurotoxin type A in female patients with upper facial rhytids: Safety and efficacy. J. Am. Acad. Derm. 2009, 60, 972–979. [Google Scholar] [CrossRef]
  93. Kerscher, M.; Rzany, B.; Prager, W.; Turnbull, C.; Trevidic, P.; Inglefield, C. Efficacy and safety of IncobotulinumtoxinA in the Treatment of Upper Facial Lines: Results From a randomized, double-blind, placebo-controlled, phase III study. Derm. Surg. 2015, 41, 1149–1157. [Google Scholar] [CrossRef]
  94. Cheon, H.I.; Jung, N.; Won, C.H.; Kim, B.J.; Lee, Y.W. Efficacy and safety of Prabotulinumtoxin A and Onabotulinumtoxin A for Crow’s feet: A phase 3, multicenter, randomized, double-blind, split-face study. Derm. Surg. 2019, 45, 1610–1619. [Google Scholar] [CrossRef]
  95. Carruthers, J.; Carruthers, A.; Monheit, G.D.; Davis, P.G. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: Satisfaction and patient-reported outcomes. Dermatol. Surg. 2010, 36 (Suppl. S4), 2135–2145. [Google Scholar] [CrossRef]
  96. Cohen, J.L.; Dayan, S.H.; Cox, S.E.; Yalamanchili, R.; Tardie, G. OnabotulinumtoxinA dose-ranging study for hyperdynamic perioral lines. Derm. Surg. 2012, 38, 1497–1505. [Google Scholar] [CrossRef] [PubMed]
  97. Kandhari, R.; Imran, A.; Sethi, N.; Rahman, E.; Mosahebi, A. Onabotulinumtoxin Type A Dosage for upper face expression lines in males: A systematic review of current recommendations. Aesthet. Surg. J. 2021, 41, 1439–1453. [Google Scholar] [CrossRef] [PubMed]
Toxins 15 00082 g001 550
Figure 1. Frontalis muscles. (A) Injection points (green dot), facial photographs (B) before injection, (C) after injection. FM, frontalis muscle; OOc, orbicularis oculi; CSM, corrugator supercilia.
Figure 1. Frontalis muscles. (A) Injection points (green dot), facial photographs (B) before injection, (C) after injection. FM, frontalis muscle; OOc, orbicularis oculi; CSM, corrugator supercilia.
Toxins 15 00082 g001
Toxins 15 00082 g002 550
Figure 2. Glabella injection points. FM, frontalis muscle; OOc, orbicularis oculi; CSM, corrugator supercilia.
Figure 2. Glabella injection points. FM, frontalis muscle; OOc, orbicularis oculi; CSM, corrugator supercilia.
Toxins 15 00082 g002
Toxins 15 00082 g003 550
Figure 3. Lateral canthal (A) injection points, (B) before injection, (C) after injection. FM, frontalis muscle; OOc, orbicularis oculi; CSM, corrugator supercilia.
Figure 3. Lateral canthal (A) injection points, (B) before injection, (C) after injection. FM, frontalis muscle; OOc, orbicularis oculi; CSM, corrugator supercilia.
Toxins 15 00082 g003
Toxins 15 00082 g004 550
Figure 4. Infraorbital rhytides injection points. OOc, orbicularis oculi; CSM, corrugator supercilia.
Figure 4. Infraorbital rhytides injection points. OOc, orbicularis oculi; CSM, corrugator supercilia.
Toxins 15 00082 g004
Toxins 15 00082 g005 550
Figure 5. Bunny lines (A) injection points, (B) before injection, (C) after injection. LLSAN, levator labii superioris alaeque nasi; LLS, levator labii sup; Zmi, zygomaticus minor; CSM, corrugator supercilia.
Figure 5. Bunny lines (A) injection points, (B) before injection, (C) after injection. LLSAN, levator labii superioris alaeque nasi; LLS, levator labii sup; Zmi, zygomaticus minor; CSM, corrugator supercilia.
Toxins 15 00082 g005
Toxins 15 00082 g006 550
Figure 6. Gummy smile (A) injection points, (B) before injection, (C) after injection. LLSAN, Levator labii superioris alaeque nasi; LLS, Levator labii superioris; Zmi: zygomaticus minor; OOr: orbicularis oris, DAO: depressor anguli oris.
Figure 6. Gummy smile (A) injection points, (B) before injection, (C) after injection. LLSAN, Levator labii superioris alaeque nasi; LLS, Levator labii superioris; Zmi: zygomaticus minor; OOr: orbicularis oris, DAO: depressor anguli oris.
Toxins 15 00082 g006
Toxins 15 00082 g007 550
Figure 7. Perioral rhytides injection points. OOR, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Figure 7. Perioral rhytides injection points. OOR, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Toxins 15 00082 g007
Toxins 15 00082 g008 550
Figure 8. Masseter (A) injection points, (B) before injection, (C) after injection. Zmi, zygomaticus minor; ZMj, zygomaticus major; OOr, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Figure 8. Masseter (A) injection points, (B) before injection, (C) after injection. Zmi, zygomaticus minor; ZMj, zygomaticus major; OOr, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Toxins 15 00082 g008
Toxins 15 00082 g009 550
Figure 9. Parotid gland injection points. Zmi, zygomaticus minor; ZMj, zygomaticus major; DAO, depressor anguli oris.
Figure 9. Parotid gland injection points. Zmi, zygomaticus minor; ZMj, zygomaticus major; DAO, depressor anguli oris.
Toxins 15 00082 g009
Toxins 15 00082 g010 550
Figure 10. Depressor anguli oris (DAO) (A) injection points, (B) before injection, (C) after injection. OOr, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Figure 10. Depressor anguli oris (DAO) (A) injection points, (B) before injection, (C) after injection. OOr, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Toxins 15 00082 g010
Toxins 15 00082 g011 550
Figure 11. Mentalis (A) injection points, (B) before injection, (C) after injection. OOr, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Figure 11. Mentalis (A) injection points, (B) before injection, (C) after injection. OOr, orbicularis oris; DAO, depressor anguli oris; DLI, depressor labii inferioris.
Toxins 15 00082 g011
Toxins 15 00082 g012 550
Figure 12. Ultrasonography imaging with outline of the muscle (yellow dotted line) (A) masseter, (B) masseter with needle tip (orange arrow).
Figure 12. Ultrasonography imaging with outline of the muscle (yellow dotted line) (A) masseter, (B) masseter with needle tip (orange arrow).
Toxins 15 00082 g012
Table
Table 1. Consensus recommendations using Botulinum toxin A for the cosmetic treatment of various indications in the upper face.
Table 1. Consensus recommendations using Botulinum toxin A for the cosmetic treatment of various indications in the upper face.
AuthorsIndication
ForeheadGlabellaCrow’s FeetInfraorbitalBunny Lines
Total Dose
(U)		IP (n)Total Dose
(U)		IP (n)Total Dose
(U)		IP (n)Total Dose (U)IP (n)Total Dose
(U)		IP (n)
Dose per IP (U)Dose per IP (U)Dose per IP (U)Dose per IP (U)Dose per IP (U)
Carruthers et al., 2004, 2008 [33,34]F: 6–15
M: 6–15		4–8F: 10–30
M: 20–40		5–7F: 10–30
M: 20–30		2–5/sideNRNR2–51/side
Carruthers et al., 2013 [35] 5–154–10F: 10–50
M: 20–60		5–710–302–5/sideNRNRNRNR
Raspaldo et al., 2011 [38,39]F: 10–20
M: 10–30		3–58–252–56–16/side3–4/side2–41–2/side 4–81/side
1–24–52–40.5–22–4
Maas et al., 2012 [44]11.75
(range: 5–30)		620
(range: 12–25)		520
(range: 6–30)		3/side4
(range: 1.5–8)		1/side 6
(range: 2–12)		1/side
Imhof et al., 2013 [45]F: 8
M: 12		4–62054–63/side22/side21/side
0.5–241–30.51
Lorenc et al., 2013 [46]F: 10–20
M: 20–40		4–620
(range: 10–40)		58–16/side4/side1
(range: 0.5–2.5)		1/sideNRNR
Yuskovskaya et al., 2015 [43]10–204–820612/side3/sideNRNR4–81/side
2–42–542–4
Sundaram et al., 2016 [47,48]8–254–812–403–76–15/side1–5/side0.5–2/side1–3/side4–8,102–3
2–42–41–40.5–22–4
De Maio et al., 2017 [49,50,51]NR5–7NR5NR3/sideNR1/side4–62 or 3
2
Kaminer et al., 2020 [52]F: 2–20
M: 4–30		2–12F: 6–35
M: 8–40		3–86–202–6/sideNRNR2–101–2/side
Signorini et al., 2022 [53] 205–10305–7183/side1–21/side 4–61/side
2–4660.5–12–3
U, unit; IP, injection point; n, number; F, female; M, male; NR, not reported; Up, upper lip; L, lower lip.
Table
Table 2. Consensus recommendations for patients using BoNT for the cosmetic treatment of various indications in the lower face.
Table 2. Consensus recommendations for patients using BoNT for the cosmetic treatment of various indications in the lower face.
AuthorsIndication
PerioralGummy SmileMasseter HypertrophyParotid Gland HypertrophyDAOCobble Stone Chin
Total Dose
(U)		IP (n)Total Dose
(U)		IP (n)Total Dose
(U)		IP (n)Total Dose (U)IP (n)Total Dose
(U)		IP (n)Total Dose
(U)		IP (n)
Dose per IP (U)Dose per IP (U)Dose per IP (U)Dose per IP (U)Dose per IP (U)Dose per IP (U)
Carruthers et al., 2004, 2008 [33,34]4–52–62–41/side25–30/sideNRNRNR2–51/side4–51–2
Carruthers et al., 2013 [35]4–62–6NRNRNRNRNRNR1–151/side4–101–2
1–7.5
Raspaldo et al., 2011 [38,39]Up: 2–5
L: 2–5		Up: 2–4
L: 2–4		3–5/side1/side18–30/side1–5/sideNRNR2–5/side1–2/side6–102
~11–261–2.53–5
Maas et al., 2012 [44]5
(range: 2–12)		Up: 4
L: 2		5
(range: 2–10)		1/side32.5
(range: 20–60)		3/sideNRNR6 (range: 2–10)1/side5 (range: 3–10)2–3
Imhof et al., 2013 [45]4Up: 4
L: 2		NRNR4–62 or 3NRNR1–31/side6 (range: 2–8)2
2
Lorenc et al., 2013 [46]52NRNRNRNRNRNR51/side4–52
2.52.5
Yuskovskaya et al., 2015 [43]Up: 4–6Up: 4NRNR503/sideNRNR61/side62
1–1.5233
Sundaram et al., 2016 [47,48]1–52–51–4, 81–2/side15–401–5/sideNRNR2–4/side1–2/side4–101–4
0.5–10.5–25–1522–3
De Maio et al., 2017 [49,50,51]Up: 2–4
L: 2		U: 2–4
L: 2		6–103–56–24/side3/sideNRNR4–81/side4–81- 3
124–82–42.5
Kaminer et al., 2020 [52]2–102–8NRNR5–352–6/sideNRNR2–61–2/side2–101–4
Signorini et al., 2022 [53]1–4Up: 2–46–10325–50/side3–5/sideNRNR4–81/side8–101–2
0.5–125–10 or 7–222–44–10
U, unit; IP, injection point; n, number; F, female; M, male; NR, not reported; Up, upper lip; L, lower lip.
Table
Table 3. Consensus recommendations for Asian patients using BoNT for the cosmetic treatment of various indications.
Table 3. Consensus recommendations for Asian patients using BoNT for the cosmetic treatment of various indications.
IndicationAuthors
Ahn et al., 2013 [27]Wu et al., 2016 [30]Sundaram et al., 2016 [28]Kapoor et al., 2017 [29]
Total Dose (U)Dose per IP (U)IP (n)Total Dose (U)Dose per IP (U)IP (n)Total Dose (U)Dose per IP (U)IP (n)Total Dose (U)Dose per IP (U)IP (n)
Forehead
rhytides		6–13.51–1.56–95–121–4NR12–14
(range: 2–32)		0.1–512F: 6–8
M: 10–12		NR4–6
Glabella84312–20NR3–1010–20
(range: 6–25)		2–43–516–20NR5–7
Crow’s feet142–33/side6–12/side1–4NR6–9 (range: 4–16)/side2–43–4/side8–12/sideNR3–4/side
Infraorbital rhytides1–20.52–44–6NRNR1–20.5–12–3/siden/aNRNR
Bunny lines6234–6NRNR3–40.5–522–4/side1–22
Perioral rhytides0.8–1.20.2–0.342–8NRNR2–3
(range: 1–8)		0.5–12–62–4NRUp: 4
L: 2
Gummy smile4–62–31/side2–12NRNR2–41–222–3/sideNR2
Bulky jaw24–30/side8–103/side40–80NRNR20–404–63–5/side15–30/sideNR3/side
Parotid gland hypertrophyNRNRNRNRNRNR20–40/side4–64–6NRNRNR
DAO6–103–51/side4–6NRNR2–4/side2–41/side2–3/sideNR1/side
Cobblestone chinmild: 5
severe: 10		5mild: 1
severe: 2		4–8NRNR8
(range: 2–16)		2–41–2/side6–8NR1–2
U, unit; IP, injection points; n, number; F, female; M, male; NR, not reported; Up, upper lip; L, lower lip.
Table
Table 4. Summary of cosmetically used BoNT. The active substances, excipients, and stabilization form per vial, and the commercial brand names are shown.
Table 4. Summary of cosmetically used BoNT. The active substances, excipients, and stabilization form per vial, and the commercial brand names are shown.
US FDA-Approved
Generic Name		Active
Substance		ExcipientUnit/
Vial		Stabilization (form)Commercial Products
OnabotulinumtoxinAComplex
(900 kDa)		HSA 0.5 mg,
NaCl 0.9 mg		100Vacuum-dried (P)Botox®,
Botox Cosmetic®, Vistabel®, Vistabex®
AbobotulinumtoxinAComplex
(500–900 kDa)		HSA 0.125 mg, Lactose 2.5 mg500Lyophilized (P)Dysport®,
Reloxin®,
Azzalure®
IncobotulinumtoxinAComplex-free (150 kDa)HSA 1 mg,
Sucrose 4.7 mg
L-methionine (q.s.)		100Lyophilized (P)Xeomin®
Bocouture®
LanbotulinumtoxinAComplex
(900 kDa)		Gelatin 5 mg, Dextran 25 mg, Sucrose 25 mg100Lyophilized (P)BTXA®,
Prosigne®,
Lantox®
LetibotulinumtoxinAComplexHSA 0.5 mgNaCl 0.9 mg100Lyophilized (P)Botulax®,
Regenox®,
Zentox®
PrabotulinumtoxinAComplex
(900 kDa)		HSA 0.5 mgNaCl 0.9 mg100Vacuum-dried (P)Nabota®, Jeuveau®,
Nuceiva®
N/AComplex
(940 kDa)		HSA 0.5 mgNaCl 0.9 mg100Lyophilized (P)Meditoxin®,
Neuronox®
N/AComplex
(900 kDa)		Gelatin 6 mg, Maltose 12 mg100Lyophilized (P)Relatox®
N/AComplexPolysorbate25LInnotox®
N/AComplex-free (150 KDa)Polysorbate 20 (q.s.)
Sucrose 3 mg
NaCl 0.9 mg		100Lyophilized (P)Coretox®
DaxibotulinumtoxinAPurified toxin
(150 kDa)		Peptide (RTP004)
Polysorbate 20
sugar		100Lyophilized (P)DAXXIFY®
RimabotulinumtoxinBComplex (700 kDa)HSA 0.5 mg
NaCl 5.844 mg
Sodium succinate 1.621 mg		5000LNeurobloc®,
Myobloc®
HSA, Human Serum Albumin; NACL, sodium chloride; P, powder; L, liquid; q.s., quantum sufficit.
Table
Table 5. Facial treatment areas in correlation with the target muscles, total amount of botulinum toxin, and number of injection points.
Table 5. Facial treatment areas in correlation with the target muscles, total amount of botulinum toxin, and number of injection points.
Facial Treatment
Areas		Target MusclesTotal DoseDose per IPNumber of
IP
Forehead rhytidesFrontalis6–20 U0.5–1 U4–6/row
(2 rows)
Glabella
(Frown lines)		Corrugator supercilia,
Procerus,
Depressor supercilii		12–30 U2–4 U3–5
Crow’s feet
(Lateral canthal lines)		Lateral orbicularis oculi4–16 U/side2–4 U3–4/side
Infraorbital rhytidesOrbicularis oculi2–4 U0.5–1 U2–3/side
Bunny lines
(Nasal rhytides)		Nasalis (transverse)
Levator labii superioris alaeque nasi		3–4 U1.5–2 U2
Perioral rhytides
(lipstick lines, smoker’s lines)		Orbicularis oris2–3 U0.5 U4–6
Gummy smileLevator labii superioris,
Levator labii superioris alaeque nasi,
Zygomaticus minor		2–6 U1–2 U1–2/side
Bulky jawMasseter15–30 U/side5 U3–5/side
Hypertrophic parotid gland Parotid gland20–40 U4–6 U4–6/side
Drooping oral commissures (frown lines, DAO)Depressor anguli oris4–10 U2–5 U2
Cobblestone chinMentalis8–10 U2–4 U2
U, unit; IP, insertion point. Numbers in the table are adapted from consensus literature summarized in Table 1, Table 2 and Table 3.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hong, S.O. Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques. Toxins 2023, 15, 82. https://doi.org/10.3390/toxins15020082

AMA Style

Hong SO. Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques. Toxins. 2023; 15(2):82. https://doi.org/10.3390/toxins15020082

Chicago/Turabian Style

Hong, Sung Ok. 2023. "Cosmetic Treatment Using Botulinum Toxin in the Oral and Maxillofacial Area: A Narrative Review of Esthetic Techniques" Toxins 15, no. 2: 82. https://doi.org/10.3390/toxins15020082

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop